The Dutch college of general practitioners standard: Erectile dysfunction;NHG-standaard erectiele disfunctie

Huisarts en Wetenschap

Volumn 51, Issue 8, 2008, Pages 381-394

  Leusink, P ^a   De Boer, L J ^a   Vliet Vlieland, C W ^a   Rambharose, V R ^a   Sprengers, A M ^a   Mogendorff, S W ^a   Van Rijn Van Kortenhof, N M M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLARITHROMYCIN; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; PHOSPHODIESTERASE V INHIBITOR; PROTEINASE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VORICONAZOLE;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COLLEGE; COMORBIDITY; CULTURAL FACTOR; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; DYSPEPSIA; EJACULATION; ERECTILE DYSFUNCTION; GENERAL PRACTITIONER; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; ISCHEMIC OPTIC NEUROPATHY; NETHERLANDS; OBESITY; PATHOPHYSIOLOGY; PRIAPISM; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

EID: 50149114473     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03086841     Document Type: Review

References (124)

1. Bij verwijzingen naar NHG-producten: zie http://www.nhg.org.
2. American Psychiatric Association. Diagnostic and statistical manual. 4th ed., text revision. Washington (DC): APA, 2000.
3. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6.
4. Aronson J. Meyler's side effects of drugs: the international encyclopedia of adverse drugs reactions and interactions. 15th ed. Amsterdam etc.: Elsevier, 2006.
5. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003;170:2356-8.
6. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003;139:161-8.
7. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. J Urol 2006;176:217-21.
8. Ballard DJ. Treatment of erectile dysfunction: can pelvic muscle exercises improve sexual function? J Wound Ostomy Continence Nurs 1997;24:255-64.
9. Banner LL, Anderson RU. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 2007;4:1117-25.
10. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med 2005;2:40-50.
11. Blanker MH, Thomas S, Bosch JL. Erectiestoornissen bij mannen van 50 jaar en ouder: prevalentie, risicofactoren en ervaren hinder. Ned Tijdschr Geneeskd 2001a;145:1035.
12. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Thomas S, et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001b;49:436-42.
13. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
14. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002;324:1059-61.
15. Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm. 2005;11:151-71.
16. Carson CC 3rd. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol. 2005;96:37M-41M
17. Cheitlin MD, Hutter AM, Jr., Brindis RG, Ganz P, Kaul S, Russell RO, Jr., et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999;99:168-77.
18. Cheng JY, Ng EM, Chen RY, Ko JS. Alcohol consumption and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res 2007;19:343-52.
19. Commissie voor Farmaceutische Hulp. Farmacotherapeutisch Kompas 2007. Amstelveen: College voor zorgverzekeringen, 2007.
20. Commissie voor Aanvullende Diagnostiek. Diagnostisch Kompas: voorlichting over aanvullende diagnostiek. Amstelveen: College voor zorgverzekeringen, 2003.
21. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61.
22. De Boer BJ, Nijeholt AA, Kleinjans HA. Intracaverneuze auto-injectietherapie met papaverine-fentolamine via een auto-injectiepen bij patiënten met een erectiestoornis: vergelijkbare resultaten bij huisarts en uroloog. Ned Tijdschr Geneeskd 2001;145:783-7.
23. De Boer BJ. Diagnostiek van erectiele disfuncties. Bijblijven 2002;5:13-20.
24. De Boer BJ. Erectile dysfunction in primary care: the ENIGMA study (proefschrift). Utrecht: Universiteit Utrecht, 2004a.
25. De Boer BJ, Bots ML, Nijeholt AA, Moors JP, Pieters HM, Verheij TJ. Erectile dysfunction in primary care: prevalence and patient characteristics. The ENIGMA study. Int J Impot Res 2004b;16:358-64.
26. Deliveliotis C, Liakouras C, Delis A, Skolarikos A, Varkarakis J, Protogerou V. Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urol Res 2004;32:283-9.
27. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000;56:302-6.
28. Dorey G, Speakman M, Feneley R, Swinkels A, Dunn C, Ewings P. Randomised controlled trial of pelvic floor muscle exercises and manometric biofeedback for erectile dysfunction. Br J Gen Pract 2004;54:819-25
29. Drory Y, Shapira I, Fisman EZ, Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995;75:835-7.
30. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005;96:1323-32.
31. Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, cross-over study. BJU Int 2007;100:122-9.
32. Ekman P, Sjogren L, Englund G, Persson BE. Optimizing the therapeutic approach of transurethral alprostadil. BJU Int 2000;86:68-74.
33. Esposito K, Giugliano F, Di PC, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978-84.
34. Evers RAF, Van Driel HA. Het non-prestatiemodel bij erectiestoornissen. Tijdschrift voor Seksuologie 1999;23:186-91.
35. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004;170:1429-37.
36. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
37. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000;30:328-38.
38. Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002;162:1349-60.
39. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-8.
40. Fulgham PF, Cochran JS, Denman JL, Feagins BA, Gross MB, Kadesky KT, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160:2041-6.
41. Gades NM, Nehra A, Jacobson DJ, McGree ME, Girman CJ, Rhodes T, et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol 2005;161:346-51.
42. Ghanem H, Porst H. Etiology and risk factors of erectile dysfunction. In: Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Malden (MA): Blackwell, 2006.
43. Gijs L, Gianotten W, Vanwesenbeeck I, Weijenborg P. Seksuologie. Houtem Bohn Stafleu Van Loghum, 2004.
44. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23.
45. Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006;50:134-40.
46. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.
47. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005;47:518-22.
48. Hauck EW, Weidner W. Francois de la Peyronie and the disease named after him. Lancet 2001;357:2049-51.
49. Hazell L, Boshier A, Harris S, Wilton LV, Shakir SA. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease. BJU Int 2007;99:387-93.
50. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. Annu Rev Sex Res 1997;8:148-94.
51. Hellstrom WJ. History, epidemiology, and clinical presentation of Peyronie's disease. Int J Impot Res. 2003; 15:S91-2.
52. Hengeveld MW, Brewaeys A. Behandelingsstrategieën bij seksuele disfuncties. Houten: Bohn Stafleu Van Loghum, 2001.
53. Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Agius PA, et al. Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2005;366:218-24.
54. IJff M. Sexcounseling in de psychosociale hulpverlening. Assen: Van Gorcum, 2002.
55. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004;1:161-7.
56. Jackson G. Erectile dysfunction, like diabetes, should be considered a 'cardiovascular equivalent'. Int J Clin Pract 2005;59:507.
57. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006;3:28-36.
58. Kaplan HS. The new sex therapy. Active treatment of sexual dysfunctions. London: Bailliere Tindall, 1974.
59. Kèdde H, Donker G. Het huisartsgeneeskundig handelen bij erectieproblemen: gegevens uit de Continue Morbiditeits Registratie Peilstations Nederland. Huisarts en Wetenschap 2006;49:410-4.
60. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-60.
61. Kloner RA, Jackson G, Hutter AM, Mittleman MA, Chan M, Warner MR, et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006;97:1778-84.
62. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7.
63. Latini DM, Penson DF, Wallace KL, Lubeck DP, Lue TF. Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. J Sex Med 2006;3:1059-67.
64. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005;17:39-57.
65. Leusink P, Van der Schoot G. 'Dat bloesje mag ook nog even uit ...': over het omgaan met seksualiteit en erotiek in het consult. Cahiers over communicatie en attitude (Cahier 20). Utrecht: Nederlands Huisartsen Genootschap, 2001.
66. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991;146:1007-9.
67. Mallis D, Moisidis K, Kirana PS, Papaharitou S, Simos G, Hatzichristou D. Moderate and severe erectile dysfunction equally affects life satisfaction. J Sex Med 2006;3:442-9.
68. Masters WH, Johnson VE. Human sexual inadequacy. London: Churchill Livingstone, 1970.
69. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002;60:28-38.
70. McLaughlin SP, Carson CC. Laboratory evaluation of the patient with erectile dysfunction. Endocrine 2004;23:113-7.
71. McMahon CG, Waldinger M, Rowland D, Assalian P. Ejaculatory disorders. In: Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Malden (MA): Blackwell, 2006.
72. Meinhardt W, Ottervanger JP, Lycklama à Nijeholt AAB, Zwartendijk J. Erectiestoornissen en priapisme door geneesmiddelen. Ned Tijdschr Geneeskd 1995;139:1871-3.
73. Melnik T, Soares BG, Nasselo AG. Psychosocial interventions for erectile dysfunction. Cochrane Database Syst Rev 2007;CD004825.
74. Meuleman EJH, Donkers LH, Robertson C, Keech M, Boyle P, Kiemeney LA. Erectiestoornis: prevalentie en invloed op de kwaliteit van leven; het Boxmeer-onderzoek. Ned Tijdschr Geneeskd 2001a; 145:576-81.
75. Meuleman EJH, Wiersma Tj, Meinhardt W, Haensel SM. NVU-Richtlijn diagnostiek en behandeling van erectiele disfunctie. Utrecht: NVU, 2001b.
76. Millett C, Wen LM, Rissel C, Smith A, Richters J, Grulich A, et al. Smoking and erectile dysfunction: findings from a representative sample of Australian men. Tob Control 2006;15:136-9.
77. Mirone V, Palmieri A, Cucinotta D, Parazzini F, Morelli P, Bettocchi C, et al. Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial. J Sex Med 2005;2:842-7.
78. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005;96:443-6.
79. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. American Urological Association guideline on the management of priapism. J Urol 2003;170:1318-24.
80. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-4.
81. Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005;5:18
82. Moors JPC. Problemen rond seksualiteit bij ouderen (4). Tijdschrift Huisartsengeneeskunde 1998;15:261-71.
83. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, et al. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004;1:69-81.
84. Mulhall J, Althof SE, Brock GB, Goldstein I, Junemann KP, Kirby M. Erectile dysfunction: monitoring response to treatment in clinical practice-recommendations of an international study panel. J Sex Med 2007;4:448-64.
85. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996;275:1405-9.
86. Nederlandse Vereniging voor Seksuologie. http://www.nvvs.info, geraadpleegd juni 2008.
87. Nederlandse Vereniging voor Bekkenproblematiek en pre- en postpartum gezondheidszorg. http://www.nvfb.nl, geraadpleegd juni 2008.
88. Nehra A. Peyronie's disease. In: Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Malden (MA): Blackwell, 2006.
89. Nicolosi A, Glasser DB, Moreira ED, Villa M. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003;15:253-7.
90. Nieuborg N, Gianotten W. Seksualiteit en cultuur: verschillen in klachten tussen autochtonen en allochtonen. Tijdschrift voor Seksuologie 2004;28:128-33.
91. Nieuwenhuijzen Kruseman AC. Laat hypogonadisme ('late-onset hypogonadism') bij mannen: onzekere ziekte-entiteit en reserves bij de behandeling met testosteron. Ned Tijdschr Geneeskd 2006;150:1925-8.
92. NIH. Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
93. NKUDIC (National Kidney and Urologic Diseases Information Clearinghouse). Peyronie's disease. NIH-Publication 06-3902. Bethesda (MD): NIH, 2005.
94. Padma-Nathan H, Hellstrom WI, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7.
95. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121-5.
96. Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Malden (MA): Blackwell, 2006a.
97. Porst H, Adaikan G. Self-injection, trans-urethral and topical therapy in erectile dysfunction In: Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Malden. MA: Blackwell Publishing, 2006b.
98. Poulakis V, Ferakis N, Witzsch U, De Vries R, Becht E. Erectile dysfunction after transurethral prostatectomy for lower urinary tract symptoms: results from a center with over 500 patients. Asian J Androl 2006;8:69-74.
99. Pourmand G, Alidaee MR, Rasuli S, Maleki A, Mehrsai A. Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study. BJU Int 2004;94:1310-3.
100. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ 2000;321:499-503.
101. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92.
102. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.
103. Rubio-Aurioles E. Hypoactive Sexual Desire in Men. In: Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Malden (MA): Blackwell, 2006.
104. Schippers J. De behandeling van seksuele klachten bij een groep Turkse en Marokkaanse mannen. Tijdschrift voor Seksuologie 2001;25:59-65.
105. Schouten BW, Bohnen AM, Bosch JL, Bernsen RM, Deckers JW, Dohle GR, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008;20:92-9.
106. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int 2001;88:727-30.
107. Seftel AD. Diagnosis of eectile dysfunction. In: Porst H, Buvat J, Adaikan G, Alexander J, Althof E, editors. Standard practice in sexual medicine. Maiden (MA): Blackwell Publishing, 2006.
108. Shiri R, Hakkinen J, Koskimaki J, Huhtala H, Auvinen A, Hakama M, et al. Association between the bothersomeness of lower urinary tract symptoms and the prevalence of erectile dysfunction. J Sex Med 2005;2:438-44.
109. Shiri R, Koskimaki J, Hakkinen J, Auvinen A, Tammela TL, Hakama M. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2007;19:208-12.
110. Slob AK, Buitenhuis EF, Gijs L, Hop WC. De 'Leidse impotentiescreeningstest' (LIST) bij mannen met een erectiestoornis als voorselectie voor psychofysiologisch diagnostisch onderzoek. Ned Tijdschr Geneeskd 2001;145:581-6.
111. Speckens AE, Hengeveld MW, Nijeholt GA, Van Hemert AM, Hawton KE. Discrimination between psychogenic and organic erectile dysfunction. J Psychosom Res 1993;37:135-45.
112. Speel TG, Van Langen H, Meuleman EJ. The risk of coronary heart disease in men with erectile dysfunction. Eur Urol 2003;44:366-70
113. Taher A. Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors. World J Urol 2004;22:457-60.
114. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
115. Tolra JR, Campana JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006;3:901-9.
116. Travison TG, Shabsigh R, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study. J Urol 2007;177:241-6.
117. Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisartspraktijk. Utrecht/Bilthoven: NIVEL/RIVM, 2004.
118. Van Lankveld JJ, Van den Hout MA, Spigt MG, Van Koeveringe GA. Cognitive changes predict continued recovery of erectile functioning versus relapse after discontinuation of sildenafil treatment for male erectile dysfunction. Psychosom Med 2003;65:709-18.
119. Van Lankveld JJ. Naar de 7e hemel. Haarlem: Aramith, 2004.
120. Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004;45:499-507.
121. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534-43.
122. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83:21C-8C.
123. Wylie KR. Treatment outcome of brief couple therapy in psychogenic male erectile disorder. Arch Sex Behav 1997;26:527-45.
124. Wylie KR, Ralph D. Premature ejaculation: the current literature. Curr Opin Urol 2005;15:393-8.